PapersPMID:41599921
Phytotherapeutic Supplementation with Momordica charantia: Beneficial Effects in Patients with Suboptimal Glycemic Control on Double Antidiabetic Therapy-A Real-World Evidence Observational Study.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- cohort
- Dose studied, every finding
- 450 mg three times daily after meals, for 3 months, added to metformin and dapagliflozin
- Population, every finding
- Adults with type 2 diabetes on metformin plus dapagliflozin 10 mg/day for 6 months who still had HbA1c of 6.5% or more; compared over months 6 to 9 with patients who had reached HbA1c below 6.5% and continued dual therapy alone
What moved
How to read these marks →“Patients receiving adjunctive Momordica charantia supplementation demonstrated a significantly greater reduction in HbA1c and fasting plasma glucose compared with patients continuing dual antidiabetic therapy alone.”
- Decreases fasting blood glucose
moderate
Study record
- Design
- cohort study
- Species
- human
- Population
- adults with type 2 diabetes mellitus on metformin with inadequate glycemic control, Oradea, Romania
- Participants
- 155
- Comparator
- no treatment
- Duration
- 274 days
- Endpoints measured
- 36